Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients

References

• Arii S, Mise M, Harada T, Furutani M, Ishigami S, Niwano M, Mizumoto M, Fukumoto M, Imamura M. (1996). Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24:316–322.
   PubMedGoogle Scholar
• Bae MH, Lee MJ, Bae SK, Lee OH, Lee YM, Park BC, Kim KW. (1998). Insulin-like growth factor II (IGF-II) secreted from HepG2 human hepatocellular carcinoma cells shows angiogenic activity. Cancer Lett 128:41–46.
   PubMed Web of Science ®Google Scholar
• Baghdiguian S, Verrier B, Gerard C, Fantini J. (1992). Insulin like growth factor I is an autocrine regulator of human colon cancer cell differentiation and growth. Cancer Lett 62:23–33.
   PubMed Web of Science ®Google Scholar
• Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJ. (1996). Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 110:821–831.
   PubMed Web of Science ®Google Scholar
• Bottomley MJ, Webb NJ, Watson CJ, Holt PJ, Freemont AJ, Brenchley PE. (1999). Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid. Clin Exp Immunol 117:171–176.
   PubMed Web of Science ®Google Scholar
• Breuhahn K, Longerich T, Schirmacher P. (2006). Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25:3787–3800.
   PubMed Web of Science ®Google Scholar
• Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563–566.
   PubMed Web of Science ®Google Scholar
• Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. (1992). Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75:1046–1053.
   PubMed Web of Science ®Google Scholar
• Curran S, Murray GI. (1999). Matrix metalloproteinases in tumour invasion and metastasis. j Pathol 189:300–308.
   PubMed Web of Science ®Google Scholar
• Daughaday WH. (1990). The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 127:1–4.
   PubMed Web of Science ®Google Scholar
• Dong ZZ. (2006). Expressions of hepatoma and circulating TGF-b1-mRNA and its clinical values in diagnosis of patients with liver cancer. J Gastroenterol Hepatol 21.
   Web of Science ®Google Scholar
• Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, Jiang DR, Zhu JH, Meng XY. (2005). Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol 11:4655–4660.
   PubMed Web of Science ®Google Scholar
• Fiorentino M, Grigioni WF, Baccarini P, D’Errico A, De Mitri MS, Pisi E, Mancini AM. (1994). Different in situ expression of insulin-like growth factor type II in hepatocellular carcinoma. An in situ hybridization and immunohistochemical study. Diagn Mol Pathol 3:59–65.
   PubMedGoogle Scholar
• Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, Schiraldi O, Antonaci S. (2002). Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 97:425–431.
   PubMed Web of Science ®Google Scholar
• Giovannucci E. (1999). Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res 51 (Suppl 3):34–41.
   PubMedGoogle Scholar
• Gong Y, Cui L, Minuk GY. (2000). The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma. Mol Cell Biochem 207:101–104.
   PubMed Web of Science ®Google Scholar
• Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y, Saisho H. (1996). Elevated plasma levels of matrix metalloproteinase-9 (92-kDa type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 24:1058–1062.
   PubMed Web of Science ®Google Scholar
• Hojo Y, Ikeda U, Zhu Y, Okada M, Ueno S, Arakawa H, Fujikawa H, Katsuki T, Shimada K. (2000). Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol 35:968–973.
   PubMed Web of Science ®Google Scholar
• Huynh H, Chow PK, Ooi LL, Soo KC. (2002). A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 13:115–122.
   PubMedGoogle Scholar
• Jie S, Li H, Tian Y, Guo D, Zhu J, Gao S, Jiang L. (2010). Berberine inhibits angiogenic potential of Hep G2 cell line through VEGF down-regulation in vitro. J Gastroenterol Hepatol 26:179–185.
   Web of Science ®Google Scholar
• Kiess W, Yang Y, Kessler U, Hoeflich A. (1994). Insulin-like growth factor II (IGF-II) and the IGF-II/mannose-6-phosphate receptor: the myth continues. Horm Res 41 (Suppl 2):66–73.
   PubMedGoogle Scholar
• Kuyvenhoven JP, van Hoek B, Blom E, van Duijn W, Hanemaaijer R, Verheijen JH, Lamers CB, Verspaget HW. (2003). Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma. Thromb Haemost 89:718–725.
   PubMed Web of Science ®Google Scholar
• Li X, Cui H, Sandstedt B, Nordlinder H, Larsson E, Ekström TJ. (1996). Expression levels of the insulin-like growth factor-II gene (IGF2) in the human liver: developmental relationships of the four promoters. J Endocrinol 149:117–124.
   PubMed Web of Science ®Google Scholar
• Lichtinghagen R, Huegel O, Seifert T, Haberkorn CI, Michels D, Flemming P, Bahr M, Boeker KH. (2000). Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 46:183–192.
   PubMed Web of Science ®Google Scholar
• Määttä M, Soini Y, Liakka A, Autio-Harmainen H. (2000). Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 6:2726–2734.
   PubMed Web of Science ®Google Scholar
• Martin DC, Fowlkes JL, Babic B, Khokha R. (1999). Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol 146:881–892.
   PubMed Web of Science ®Google Scholar
• Matsumoto E, Nakatsukasa H, Nouso K, Nakamura SI, Suzuki M, Kobayashi Y, Uemura M, Sato S, Yumoto EI, Yokoyama J, Tsuboi S, Tanaka H, Takuma Y, Fujikawa T, Shiratori Y. (2004). Elevated levels of tissue inhibitor of metalloproteinases (TIMPS) in human hepatocellular carcinomas. Comp Hepatol 3 Suppl 1:S51.
   PubMedGoogle Scholar
• McCusker RH, Busby WH, Dehoff MH, Camacho-Hubner C, Clemmons DR. (1991). Insulin-like growth factor (IGF) binding to cell monolayers is directly modulated by the addition of IGF-binding proteins. Endocrinology 129:939–949.
   PubMed Web of Science ®Google Scholar
• Milani S, Herbst H, Schuppan D, Grappone C, Pellegrini G, Pinzani M, Casini A, Calabró A, Ciancio G, Stefanini F. (1994). Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 144:528–537.
   PubMed Web of Science ®Google Scholar
• Murawaki Y, Ikuta Y, Okamoto K, Mimura K, Koda M, Kawasaki H. (2000). Plasma matrix metalloproteinase-9 (gelatinase B) in patients with hepatocellular carcinoma. Res Commun Mol Pathol Pharmacol 108:351–357.
   PubMedGoogle Scholar
• Nart D, Yaman B, Yilmaz F, Zeytunlu M, Karasu Z, Kiliç M. (2010). Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation. Liver Transpl 16:621–630.
   PubMed Web of Science ®Google Scholar
• Norstedt G, Levinovitz A, Möller C, Eriksson LC, Andersson G. (1988). Expression of insulin-like growth factor I (IGF-I) and IGF-II mRNA during hepatic development, proliferation and carcinogenesis in the rat. Carcinogenesis 9:209–213.
   PubMed Web of Science ®Google Scholar
• Qin LX, Tang ZY. (2004). Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 130:497–513.
   PubMed Web of Science ®Google Scholar
• Scharf JG, Dombrowski F, Ramadori G. (2001). The IGF axis and hepatocarcinogenesis. MP, Mol Pathol 54:138–144.
   PubMedGoogle Scholar
• Srivastava PK. (2005). Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep 7:104–108.
   PubMedGoogle Scholar
• Stuver SO, Kuper H, Tzonou A, Lagiou P, Spanos E, Hsieh CC, Mantzoros C, Trichopoulos D. (2000). Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 87:118–121.
   PubMed Web of Science ®Google Scholar
• Sun MH, Han XC, Jia MK, Jiang WD, Wang M, Zhang H, Han G, Jiang Y. (2005). Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 11:5931–5937.
   PubMed Web of Science ®Google Scholar
• Toropainen EM, Lipponen PK, Syrjanen KJ. (1995). Expression of insulin-like growth factor II in female breast cancer as related to established prognostic factors and long-term prognosis. Anticancer Res 15:2669–2674.
   PubMed Web of Science ®Google Scholar
• Yao D, Jiang D, Huang Z, Lu J, Tao Q, Yu Z, Meng X. (2000). Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 88:761–769.
   PubMed Web of Science ®Google Scholar
• Yao DF. (2006). Abnormal expression of transforming growth factor-beta1 in hepatocellular carcinoma and pathological characteristics of its relationship with HBV replication. J Gastroenterol Hepatol 21.
   Web of Science ®Google Scholar
• Yao DF, Dong ZZ, Yao M. (2007). Specific molecular markers in hepatocellular carcinoma. Hbpd Int 6:241–247.
   Google Scholar
• Yao DF, Huang ZW, Chen SZ, Huang JF, Lu JX, Xiao MB, Meng XY. (1998). Diagnosis of hepatocellular carcinoma by quantitative detection of hepatoma-specific bands of serum gamma-glutamyltransferase. Am j Clin Pathol 110:743–749.
   PubMed Web of Science ®Google Scholar
• Yao DF, Wu XH, Su XQ, Yao M, Wu W, Qiu LW, Zou L, Meng XY. (2006). Abnormal expression of HSP gp96 associated with HBV replication in human hepatocellular carcinoma. Hbpd Int 5:381–386.
   Google Scholar
• Yeh HC, Lin SM, Chen MF, Pan TL, Wang PW, Yeh CT. (2010). Evaluation of serum matrix metalloproteinase (MMP)-9 to MMP-2 ratio as a biomarker in hepatocellular carcinoma. Hepatogastroenterology 57:98–102.
   PubMedGoogle Scholar
• Ylisirniö S, Höyhtyä M, Mäkitaro R, Pääakkö P, Risteli J, Kinnula VL, Turpeenniemi-Hujanen T, Jukkola A. (2001). Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 7:1633–1637.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, Xu J, Qian F, Chen Z. (2006). CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 5:808–814.
   PubMed Web of Science ®Google Scholar
• Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C, Lai MM. (1998). Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 72:3691–3697.
   PubMed Web of Science ®Google Scholar